This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Forest Laboratories Names Alex Kelly Senior Vice President, Chief Communications Officer, Public Affairs And Investor Relations

Forest Laboratories, Inc. (NYSE:FRX) today announced that Alex Kelly has been named Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations. In this role, Alex will lead Forest’s corporate communications and investor relations (IR) programs, including internal and external communications, media relations, corporate branding, product communications, and public affairs. He will serve as top advisor to the Forest leadership team with regard to all matters related to the company’s reputation, messaging, and external communications strategy. Additionally, he will collaborate in the development of corporate strategy and serve as a corporate spokesperson. Kelly will report to Brent Saunders, Chief Executive Officer and President. Frank Murdolo, Vice President Investor Relations, will continue in his role and report directly to Kelly.

“Alex brings to Forest extensive executive experience in global communications and investor relations from a career that spans more than 24 years in the pharmaceutical industry,” said Brent Saunders. “By unifying our communications under Alex, Forest will enhance its engagement with key stakeholders at this important time for the Company.”

Kelly most recently served as Vice President, Investor Relations at Bausch + Lomb after serving as Senior Vice President, Investor Relations at Merck & Co., Inc. Prior to Merck, he led the Global Communications and IR team for Schering-Plough and was responsible for internal and external communications, IR, media relations, product communications, web site and corporate branding. He previously worked for Novartis and Pharmacia, where he spent ten years in pharmaceutical sales and sales management.

Kelly holds a Bachelor of Science in Pharmacy from Purdue University, where he graduated Cum Laude.

About Forest Laboratories

Forest Laboratories' (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, gastrointestinal and pain management medicine. Forest’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. Forest assumes no obligation to update forward-looking statements contained in this release to reflect new information or future events or developments.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs